24
Participants
Start Date
July 1, 2021
Primary Completion Date
July 21, 2022
Study Completion Date
September 1, 2022
liraglutide 3 mg (Saxenda®) once-daily
Liraglutide 3 mg (Saxenda®) 6 mg/ml, 3 ml pre-filled pen-injector. The injection is administered subcutaneously. The initial daily dose will be 0.6 mg liraglutide (Saxenda®) for one week. If tolerated patients increase the dose by +0.6 mg each week until the full maintenance of 3 mg is reached (week 1: 0.6 mg, week 2: 1.2 mg, week 3: 1.8 mg, week 4: 2.4 mg, week 5-26: 3.0 mg. If necessary, a longer titration period is accepted). If the lowest tolerated dose is less than 1.8 mg of liraglutide (Saxenda®) once-daily after 12 weeks from inclusion, the patient will be excluded from the study.
Psychiatric Centre Sct.Hans. Forensic Mental Health Services in the Capitol Region of Denmark., Roskilde
Anders Fink-Jensen, MD, DMSci
OTHER